CN104173665A - Pharmaceutical composition for treating osteoproliferation - Google Patents
Pharmaceutical composition for treating osteoproliferation Download PDFInfo
- Publication number
- CN104173665A CN104173665A CN201410412499.7A CN201410412499A CN104173665A CN 104173665 A CN104173665 A CN 104173665A CN 201410412499 A CN201410412499 A CN 201410412499A CN 104173665 A CN104173665 A CN 104173665A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- parts
- radix
- rhizoma
- hyperosteogeny
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to pharmaceutical composition medicinal liquor for treating osteoproliferation. The pharmaceutical composition is prepared from lycopodium clavatum, Caulis Spatholobi, herba epimedii, rehmannia glutinosa, Eucommia ulmoides, Chinese yam, red flower, notopterygium root, Sappanwood and radix achyranthis bidentatae. The invention aims to provide a medicine which has an exact curative effect and is used for treating osteoproliferation.
Description
Technical field
The invention belongs to field of medicaments, be specifically related to a kind of pharmaceutical composition for the treatment of hyperosteogeny and preparation method thereof.
Background technology
Hyperosteogeny is a kind of person in middle and old age's chronic disease common on Orthopedic Clinical, is a kind of performance of femoral joint degeneration, and generally speaking patient's chronic arthritis is exactly because the hyperosteogeny at edge, joint is caused.The patient of hyperosteogeny often there will be ankylosis, tired and be attended by pain, and after activity, symptom takes a turn for the better, but activity aggravation or continuously active after, turns again weight, has caused very large obstruction for live and work.
Summary of the invention
Goal of the invention of the present invention is to provide a kind of new Chinese medicine for the treatment of hyperosteogeny and preparation method thereof, reduce patient's pain, there is expelling wind and cold, stasis-dispelling and pain-killing, warming the kidney to activate YANG, the effect of bone and muscle strengthening, and easy to use, formula is simple, onset is rapid, evident in efficacy, removes patient's sufferings, creates good society and economic benefit.
Drug regimen raw material of the present invention is by weight ratio: 15 parts of Herba Lycopodiis, 15 parts of Caulis Spatholobis, 13 parts of Herba Epimedii, 12 parts, Radix Rehmanniae Preparata, 12 parts of the Cortexs Eucommiae, 12 parts of Rhizoma Dioscoreaes, 10 parts, Flos Carthami, 10 parts of Rhizoma Et Radix Notopterygiis, 10 parts of Lignum Sappans, 10 parts of Radix Achyranthis Bidentataes.
The preparation method of above pharmaceutical composition is: more than 50 ° in Chinese liquor, soak 20 days at the above drug regimen raw material of weighing scale 8 times (volumes), obtain pharmaceutical composition medicated wine of the present invention.
Herba Lycopodii: expelling wind and cold, dehumidifying detumescence, relaxing muscles and tendons and activating QI and blood in the collateral.Modern pharmacy studies have shown that, Herba Lycopodii has cooling, diuresis, controls the effects such as ventilation.
Caulis Spatholobi: enrich blood, invigorate blood circulation, dredging collateral.Modern pharmacy studies have shown that; rattan is containing epifriedelanol, daucosterol, cupreol, 7-ketone group-cupreol, formoononetin, ononin, prunusetin., afromosin, Dai, 3; 7-dihydroxy-6-melonia flavonol, epicatechin, Isoliquiritigenin etc., have anticoagulation, reduce blood pressure, the effect such as lipid metabolism adjusting.
Herba Epimedii: warming YANG kidney tonifying, expelling wind and removing dampness.Modern pharmacy studies have shown that, contains the materials such as flavone compound, lignin, alkaloid, volatile oil, icariine, sterol, can antibacterial, blood pressure lowering.
Radix Rehmanniae Preparata: the YIN nourishing of enriching blood, beneficial essence are filled out marrow.Modern pharmacy studies have shown that, Radix Rehmanniae Preparata water decoction gavages to posthemorrhagic anemia mice, can promote the recovery of anemia animal erythrocyte, hemoglobin, accelerates pluripotential hemopoietic stem cell, the propagation of bone marrow hemopoietic progenitor cell of red blood cell line, differentiation; Radix Rehmanniae Preparata can significantly suppress liver hemorrhagic necrosis kitchen range and simple necrosis.The hyperlipemia that high lipid food is caused, the hepatic vein hemorrhage that fatty liver and rat endotoxin cause, all has the thrombotic effect of inhibition.Thinking activation to plasminogen, is antithrombotic mechanism of action.In addition the effect that, also there is antioxidation, improves immunity.
The Cortex Eucommiae: liver and kidney tonifying, bone and muscle strengthening.Modern pharmacy studies have shown that, Cortex Eucommiae extract can obviously improve castrated rats bone biomechanical level, effectively prevents the generation of fracturing due to osteoporosis.
Rhizoma Dioscoreae: strengthening the spleen and tonifying the lung, stomach reinforcing the kidney invigorating.Modern pharmacy studies have shown that, Rhizoma Dioscoreae is rich in several amino acids, trace element, mineral, and vitamin has strong body, the effect of kidney nourishing and replenishing vital essence.
Flos Carthami: promoting blood circulation to restore menstrual flow, stasis-dispelling and pain-killing.Modern pharmacy studies have shown that, Flos Carthami contains Carthamus yellow, has the effect of good anticoagulation, resisting fatigue, antiinflammatory, raising immunity.
Rhizoma Et Radix Notopterygii: warming the kidney to activate YANG, improving inspiration by invigorating kidney-QI, antidiarrheal.Modern pharmacy studies have shown that, the effect such as that Rhizoma Et Radix Notopterygii has is antipyretic, antiinflammatory, analgesia.
Lignum Sappan: blood circulation promoting and blood stasis dispelling, reducing swelling and alleviating pain.Modern pharmacy studies have shown that, Lignum Sappan is for epinephrine induced mice Mesentery microcirculation obstacle, and Lignum Sappan decocting alcohol extract can significantly promote arteriole blood flow to promote the recovery of microcirculation and caliber; Cause the blood of experimental rabbits in blood stasis syndrome for quiet note high molecular dextran, Lignum Sappan injection can significantly reduce blood viscosity in vitro.
Radix Achyranthis Bidentatae: invigorating the liver and kidney, bone and muscle strengthening, eliminating blood stasis and inducing menstruation, conducting blood to flow downwards.Now study of pharmacy proves, root is containing triterpenoid saponin: oleanolic acid α-L-rhamnopyranosyl-β-D-galactopyranose glycoside.Again containing multiple polysaccharide: a kind of is the polysaccharide with anti-tumor activity settling out with acetone from the infusion of root; Be by 6 glucose residues and 3 water solublity oligosaccharide AbS that mannose residue forms, have the activity of the enhancing immunologic function showing; Another kind is to have immunocompetent peptide polysaccharide ABAB, system was by glucuronic acid, half milk extract, galacturonic acid, arabinose and rhamnose 12: 2: 1 in molar ratio: 1: 1 forms, the content of peptide is 24.7%, is mainly made up of glycine, glutamic acid, aspartic acid and serine.Effects such as thering is anti-inflammatory and antalgic, improve immunity, antitumor, be antibacterial.
In order to show that medicine of the present invention has therapeutic effect to hyperosteogeny, the present invention has carried out following clinical trial.
1 data and method
1.1 clinical data
This organizes the diagnostic criteria that 84 routine patients all meet knee joint osseous arthritis, wherein male 15 examples, female's 69 examples; 48～72 years old age, 59.3 years old mean age; The course of disease is the shortest 1 year, the longest 14 years.Unilateral knee arthropathy 67 examples, bilateral knee arthropathy 17 examples.84 routine patients are divided into two groups at random, every group of each 42 routine patients, the aspect comparing difference not statistically significants (P > 0.05) such as two groups of patient clinical datas, have comparability.
1.2 Therapeutic Method
Matched group adopts simple acupuncture and moxibustion therapy, and taking relaxing muscles and tendons and activating QI and blood in the collateral, dispelling cold by warming the meridian as the main rule for the treatment of, according to patient's diseased region, taking local point selection as main, selecting the acupoints according to the channel is auxiliary, and cervical vertebra pathological changes is taking neck paravertebral point as main; Lumbal vertebra is taking HUATUOJIAJI acupoint, the Kunlun, shen shu as main; Knee hyperplasia is taking the sea of blood, gb 34 as main; Heel hypertrophy is taking Taixi, Zhaohai, Ashi point as main, with uniform reinforcing-reducing method let the acupuncture needle remain at a certain point 30min, 1 time/d; Treatment group adds on the basis for the treatment of of control group carries out outer wiping treatment with pharmaceutical composition of the present invention, pick with gauze, wiping affected part, until patient feels slight fever, 2 times/d, is enjoined patient and family members thereof at least to retain medicated wine 2h after wiping and is cleaned above again repeatedly.
1.3 efficacy determination
Be that master judges according to the criterion of therapeutical effect of formulating in " disease of tcm diagnosis and treatment standard ", be divided into effective, effective and invalid according to therapeutic effect.Effective: patient's clinical symptom disappearance, recover orthobiosis and ability to work; Effective: patient clinical symptom is treated front remarkable improvement, although still have mild pain sense not affect orthobiosis and work; Invalid: patient clinical symptom is treated front nothing and significantly improved or occur increasing the weight of, and pain is still strong, the normal work of impact and life.With effective+effectively add up total effective rate.
1.4 statistical procedures
All data typing SPSS17.0 of two groups of patients are carried out to statistical procedures, and between group, contrast adopts t inspection, and P < 0.05 is considered as having statistical significance.
2 results
From two groups of patients' obvious effective rate and total effective rate, treatment group is significantly better than matched group (P < 0.05).Concrete data are in table 1.
Table 1 liang group patient's therapeutic effect Statistical Comparison
Note: * is compared with matched group, and P < 0.05, has significant difference
This result shows, medicine of the present invention has significant therapeutic effect to hyperosteogeny tool, and main manifestations patient clinical transference cure recovers orthobiosis and ability to work, and pain obviously alleviates.
Specific embodiment
Embodiment 1 Herba Lycopodii 15g, Caulis Spatholobi 15g, Herba Epimedii 13g, Radix Rehmanniae Preparata 12g, Cortex Eucommiae 12g, Rhizoma Dioscoreae 12g, Flos Carthami 10g, Rhizoma Et Radix Notopterygii 10g, Lignum Sappan 10g, Radix Achyranthis Bidentatae 10g.
The preparation method of above pharmaceutical composition is: drug regimen raw material soaks 20 days in 952ml50 ° of Chinese liquor, obtains pharmaceutical composition medicated wine of the present invention, and the used time is poured out medicated wine, wiping hyperosteogeny position.
Claims (4)
1. treat a pharmaceutical composition for hyperosteogeny, it is characterized in that according to weight portion meter, the raw material of making this pharmaceutical composition active component is: Herba Lycopodii, Caulis Spatholobi, Herba Epimedii, Radix Rehmanniae Preparata, the Cortex Eucommiae, Rhizoma Dioscoreae, Flos Carthami, Rhizoma Et Radix Notopterygii, Lignum Sappan, Radix Achyranthis Bidentatae.
2. a kind of pharmaceutical composition for the treatment of hyperosteogeny as claimed in claim 1, it is characterized in that according to weight portion meter, the raw material of making this pharmaceutical composition active component is: 15 parts of Herba Lycopodiis, 15 parts of Caulis Spatholobis, 13 parts of Herba Epimedii, 12 parts, Radix Rehmanniae Preparata, 12 parts of the Cortexs Eucommiae, 12 parts of Rhizoma Dioscoreaes, 10 parts, Flos Carthami, 10 parts of Rhizoma Et Radix Notopterygiis, 10 parts of Lignum Sappans, 10 parts of Radix Achyranthis Bidentataes.
3. the preparation method of a kind of pharmaceutical composition for the treatment of hyperosteogeny as claimed in claim 1 or 2, it is characterized in that the method is: more than 50 ° in Chinese liquor, soak 20 days at drug regimen raw material described in weighing scale 8 times (volumes), obtain pharmaceutical composition medicated wine.
4. the preparation method of a kind of pharmaceutical composition for the treatment of hyperosteogeny as claimed in claim 3, it is characterized in that the method is: Herba Lycopodii 15g, Caulis Spatholobi 15g, Herba Epimedii 13g, Radix Rehmanniae Preparata 12g, Cortex Eucommiae 12g, Rhizoma Dioscoreae 12g, Flos Carthami 10g, Rhizoma Et Radix Notopterygii 10g, Lignum Sappan 10g, Radix Achyranthis Bidentatae 10g, above raw material soaks 20 days in 952ml50% ethanol, obtains pharmaceutical composition medicated wine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410412499.7A CN104173665A (en) | 2014-08-16 | 2014-08-16 | Pharmaceutical composition for treating osteoproliferation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410412499.7A CN104173665A (en) | 2014-08-16 | 2014-08-16 | Pharmaceutical composition for treating osteoproliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104173665A true CN104173665A (en) | 2014-12-03 |
Family
ID=51955190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410412499.7A Pending CN104173665A (en) | 2014-08-16 | 2014-08-16 | Pharmaceutical composition for treating osteoproliferation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104173665A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102228578A (en) * | 2011-06-14 | 2011-11-02 | 李以昌 | Hot compress bag for rheumatism and related to sclerotin and manufacturing method thereof |
-
2014
- 2014-08-16 CN CN201410412499.7A patent/CN104173665A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102228578A (en) * | 2011-06-14 | 2011-11-02 | 李以昌 | Hot compress bag for rheumatism and related to sclerotin and manufacturing method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 王宾等: "中医治疗骨性关节炎研究进展", 《辽宁中医药大学学报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103705603B (en) | Traditional Chinese medicine for treating acne | |
| CN103301400B (en) | A kind of Chinese medicine composition and preparation method for the treatment of chronic atrophic gastritis | |
| CN101983644A (en) | Medicament for treating sequelae of apoplexy | |
| CN106075359A (en) | A kind of Chinese medicine composition treating fungi type tinea pedis | |
| CN105168713A (en) | Traditional Chinese medicine for treating migraine | |
| CN103127375B (en) | Chinese materia medica preparation for treating osteoporosis | |
| CN103735647A (en) | Medicated wine for treating chronic infectious arthritis | |
| CN104173665A (en) | Pharmaceutical composition for treating osteoproliferation | |
| CN104474110B (en) | A kind of medicine for treating Osteoarthritis in aged | |
| CN104511002A (en) | Anti-rheumatic pain relieving medicine | |
| CN103463463A (en) | Traditional Chinese medicine preparation for replenishing and activating blood and dispelling wind and removing dampness | |
| CN103494900A (en) | Traditional Chinese medicine for treating stiff neck | |
| CN102935156A (en) | Pills for treating hyperostosis | |
| CN105311612A (en) | Traditional Chinese medicine for treating myospasm | |
| CN104367896A (en) | Pharmaceutical composition for treating qi deficiency and blood stasis-type apoplexy and preparation method thereof | |
| CN105267706A (en) | Traditional Chinese medicine preparation for treating hyperostosis | |
| CN103933176B (en) | A kind of Chinese medicine composition for the treatment of apoplexy sequela and preparation method thereof | |
| CN105056127A (en) | Medicine combination for treating heart disease | |
| CN104666469A (en) | Traditional Chinese medicine composition for treating phase III shoulder-hand syndrome | |
| CN104587215A (en) | Traditional Chinese medicine composition for treating kidney yin deficiency | |
| CN104161935A (en) | Medicament for treating rheumatic and rheumatoid diseases | |
| CN104758673A (en) | Traditional Chinese medicine composition for treating sequelae of apoplexy | |
| CN102293879A (en) | Chinese medicinal composition for treating rheumatism | |
| CN103463294B (en) | Traditional Chinese medicine composite for treating lumbar spinal stenosis | |
| CN103638188A (en) | Chinese medicine for preventing and treating chronic osteomyelitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141203 |
|
| RJ01 | Rejection of invention patent application after publication |